PharmaCyte Biotech, Inc. Stock Price - PMCB

Best deals to access real time data!
SMALL CAP BASIC
Monthly Subscription
for only
$30.03
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$31.00
SMALL CAP PRO
Monthly Subscription
for only
$44.59
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Pharmacyte Biotech, Inc. (QB) PMCB Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.00191 +2.45% 0.0799 0.082 0.07 0.07845 0.07799 15:59:47
Bid Price Ask Price Spread Spread % News
0.076 0.08 0.004 5.00% - -
Stock Trades Traded Volume Average Volume 52 Week Range
165 1,736,168 2.89M 0.02 - 0.17
Last Trade Time Type Quantity Stock Price Currency
15:59:47 100 $0.08 USD

Pharmacyte Biotech, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 69.94M 875.31M $ -6.06M - -11.53 842.54M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
49.71k 0.01% $ - 0.00% - -

more financials information »

Pharmacyte Biotech, Inc. (QB) News

Latest PMCB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PMCB Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.070.0950.070.08181M5M4M0.009914.14%
1 Month0.0540.0950.0490.0712441k5M2M0.025947.96%
3 Months0.0760.0950.0460.0642441k14M3M0.00395.13%
6 Months0.116250.1280.0460.0834441k14M3M-0.03635-31.27%
1 Year0.0520.16890.0230.0800441k27M4M0.027953.65%
3 Years0.0510.26150.00010.0936027M2M0.028956.67%
5 Years0.31150.360.00010.0937027M1M-0.2316-74.35%

Pharmacyte Biotech, Inc. (QB) Description

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.